|
|
Volumn 9, Issue 3, 2010, Pages 227-
|
|
Antiepileptic drugs: the drawbacks of generic substitution
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTICONVULSIVE AGENT;
GENERIC DRUG;
TOPIRAMATE;
BIOEQUIVALENCE;
CANADA;
CLINICAL PRACTICE;
CONFIDENCE INTERVAL;
CONSULTATION;
CONSUMER;
DRUG COST;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG SAFETY;
DRUG SUBSTITUTION;
EDITORIAL;
EPILEPSY;
FOOD AND DRUG ADMINISTRATION;
HEAD INJURY;
HEALTH CARE COST;
HEALTH CARE POLICY;
HEALTH INSURANCE;
HUMAN;
POPULATION RESEARCH;
PRESCRIPTION;
PRIMARY MEDICAL CARE;
PRIORITY JOURNAL;
SEIZURE;
UNITED KINGDOM;
UNITED STATES;
ANTICONVULSANTS;
DRUGS, GENERIC;
HUMANS;
SEIZURES;
THERAPEUTIC EQUIVALENCY;
|
|
EID: 76449106061
PISSN: 14744422
EISSN: None
Source Type: Journal
DOI: 10.1016/S1474-4422(10)70044-2 Document Type: Editorial |
|
Times cited : (4)
|
|
References (0)
|